We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.91B
Turnover
15.22%
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter Est. Return
+21.36%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.93%
10 Year Est. Return
+28,184.7%
AUM
$567M
AUM Growth
+$88.3M
(+18%)
Cap. Flow
+$6.94M
Cap. Flow % of AUM
Cap. Flow %
1.22%
Top 10 Holdings %
Top 10 Hldgs %
70.26%
Holding
36
New
5
Increased
6
Reduced
13
Closed
6
Avg Time Held
1.1
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blueprint Medicines
BPMC
|
+$45.2M |
| 2 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
+$18M |
| 3 |
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
|
+$14.1M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$8.25M |
| 5 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$6.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ligand Pharmaceuticals
LGND
|
+$20.6M |
| 2 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
+$12M |
| 3 |
ChemoCentryx, Inc.
CCXI
|
+$8.21M |
| 4 |
Exelixis
EXEL
|
+$7.23M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$5.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.05% |
| 2 | Miscellaneous | 10.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Array Biopharma Inc
ARRY
| $66.1M | 11.67% |
9,169,276
-236,541
| -3% | -$1.75M |
2013 Q2
8 quarters
|
|
|
2
DELISTED
ChemoCentryx, Inc.
CCXI
| $59.8M | 10.56% |
7,270,013
-1,033,071
| -12% | -$8.21M |
2013 Q2
8 quarters
|
|
|
3
DELISTED
Blueprint Medicines
BPMC
| $41.9M | 7.4% |
+1,582,408
| New | +$45.2M |
2015 Q2
0 quarters
|
|
|
FWP
4
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $38.4M | 6.78% |
144,140
-24,072
| -14% | -$5.76M |
2014 Q4
2 quarters
|
|
|
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $37.5M | 6.63% |
2,521,452
+1,180,793
| +88% | +$18M |
2014 Q3
3 quarters
|
|
|
CASC
6
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $36.5M | 6.44% |
1,625,696
-760,000
| -32% | -$12M |
2013 Q2
8 quarters
|
|
|
LOXO
7
DELISTED
Loxo Oncology, Inc
LOXO
| $29.1M | 5.14% |
1,615,081
+489,416
| +43% | +$6.69M |
2014 Q3
3 quarters
|
|
|
OMED
8
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $28.5M | 5.02% |
1,264,715
-19,400
| -2% | -$478K |
2013 Q3
7 quarters
|
|
9
Ironwood Pharmaceuticals
IRWD
$806M
| $26.2M | 4.62% |
2,592,303
| – | – |
2013 Q2
8 quarters
|
|
|
VTAE
10
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $23.1M | 4.08% |
1,604,615
+27,180
| +2% | +$369K |
2014 Q3
3 quarters
|
|
|
TBRA
11
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $20.3M | 3.58% |
1,175,233
+966,064
| +462% | +$14.1M |
2013 Q3
7 quarters
|
|
12
Gyre Therapeutics
GYRE
$477M
| $18.6M | 3.28% |
8,451
| – | – |
2013 Q2
8 quarters
|
|
13
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $15.8M | 2.79% |
7,695
-242
| -3% | -$344K |
2014 Q4
2 quarters
|
|
14
DELISTED
QLT Inc
QLTI
| $15.4M | 2.72% |
3,737,446
-412,416
| -10% | -$1.58M |
2013 Q2
8 quarters
|
|
15
Cytokinetics
CYTK
$7.68B
| $14.2M | 2.5% |
2,106,989
| – | – |
2013 Q2
8 quarters
|
|
|
16
Exelixis
EXEL
$17.1B
| $10.4M | 1.84% |
2,766,152
-2,222,205
| -45% | -$7.23M |
2014 Q4
2 quarters
|
|
|
ARQL
17
DELISTED
Arqule Inc
ARQL
| $10.3M | 1.82% |
6,430,708
+256,147
| +4% | +$493K |
2013 Q2
8 quarters
|
|
|
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.7M | 1.71% |
+200,000
| New | +$8.25M |
2015 Q2
0 quarters
|
|
19
Xenon Pharmaceuticals
XENE
$3.95B
| $7.83M | 1.38% |
678,764
+287,340
| +73% | +$3.97M |
2014 Q4
2 quarters
|
|
|
FPRX
20
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $5.98M | 1.05% |
240,597
-262,235
| -52% | -$5.84M |
2013 Q4
6 quarters
|
|
21
DELISTED
Astria Therapeutics
ATXS
| $2.75M | 0.48% |
+3,750
| New | +$2.83M |
2015 Q2
0 quarters
|
|
22
Savara
SVRA
$1.03B
| $2.5M | 0.44% |
73,018
-30,433
| -29% | -$1.07M |
2014 Q4
2 quarters
|
|
23
aTyr Pharma
ATYR
$19.7M
| $2.5M | 0.44% |
+241
| New | +$2.99M |
2015 Q2
0 quarters
|
|
24
Achieve Life Sciences
ACHV
$699M
| $2.38M | 0.42% |
464
-158
| -25% | -$784K |
2014 Q2
4 quarters
|
|
|
GBIM
25
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
| $1.77M | 0.31% |
+678,400
| New | +$4.22M |
2015 Q2
0 quarters
|
|
Similar funds
LFCM
AC
BVF Inc's Q2 2015 Portfolio in Review
As of Q2 2015, BVF Inc held 36 positions worth $567M, up 18% from $478M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
BVF Inc's Q2 2015 filing shows 5 new, 6 increased, 13 reduced and 6 closed positions. Its largest new stake was Blueprint Medicines: 1,582,408 shares worth $41.9M. The largest sale was Ligand Pharmaceuticals, an estimated $20.6M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Miscellaneous.
- BVF Inc's largest Q2 2015 buy was Blueprint Medicines: 1,582,408 shares worth $41.9M.
- BVF Inc added most to Concert Pharmaceuticals, Inc. in Q2 2015, an estimated $18M increase.
- BVF Inc's biggest Q2 2015 reduction was Cascadian Therapeutics, Inc., cutting an estimated $12M.
- BVF Inc fully exited Ligand Pharmaceuticals in Q2 2015, selling an estimated $20.6M.
- BVF Inc's ten largest holdings make up 70% of its $567M portfolio in Q2 2015.
- BVF Inc opened 5 new positions and closed 6 in Q2 2015.
- BVF Inc's portfolio value rose 18% quarter-over-quarter to $567M.
Based on BVF Inc's 13F filing for Q2 2015, filed 14 Aug 2015.